Generate Biomedicines, Inc.
NASDAQ:GENBAsset Management
+$0.13 today
- Market cap
- $1.34B
- Beta
- 0.19
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$4.06
Volume 1.05M
Average 0.55M
GENB Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Generate Biomedicines, Inc.NASDAQ: GENB
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income of -$61.45M in Q1 FY2026
Q1 FY2026 net income was -$61.45M.
Context
- Net income amounted to 699.1% of revenue in FY2025, down 187.5 pp from a year earlier.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -$129.65M (-41.9%) for the fiscal year ending Dec 2026, a slowdown from the +22.9% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$61.45M— QoQ
- Last fiscal yearDec 2025
- -$222.97M+22.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | +22.9% | -41.9% | -64.8 pp |
| 3-year CAGR | — | -24.0% | — |
| 5-year CAGR | -10.3% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (222.97M) USD
- Year-over-year change
- -22.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (222.97M) | -22.9% |
| FY2024 | 2024-12-31 | (181.38M) | — |
Net Income vs competitors
How GENB compares with its peers on the latest reported figures
- GENB's FY2025 net income of $222.97M is the largest of the 5 companies compared; the peer median is $141.89M.
- Its year-over-year change of +22.9% is the highest of 5, against a peer median of -13.6%.
- Net income amounts to 699.1% of revenue for GENB, versus a peer median of 3366.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
GENBGenerate Biomedicines, Inc. | FY2025 | $222.97M | +22.9% | — | 699.1% |
| LTM Sep 2026 | $191.46M | +11.5% | — | 282.2% | |
| LTM Mar 2026 | $153.6M | -37.4% | +17.0% | 154.2% | |
| LTM Mar 2026 | $130.19M | -107.7% | -1.2% | 10014.2% | |
| LTM Mar 2026 | $118.44M | +10.2% | +3.2% | 6450.8% | |
| Peer median (excluding GENB) | $141.89M | -13.6% | +3.2% | 3366.5% | |
Competitors are the stored peer set for GENB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Net Income | (181.38M) | (222.97M) |
| Depreciation & Amortization | 15.35M | 13.18M |
| Deferred Income Tax | 0 | 0 |
| Stock-Based Compensation | 19.47M | 20.58M |
| Change in Working Capital | 28.12M | (14.62M) |
| Accounts Receivables | (213K) | 308K |
| Inventory | 0 | 0 |
| Accounts Payables | 3.5M | (2.13M) |
| Other Working Capital | 24.83M | (12.79M) |
| Other Non-Cash Items | 702K | 3.21M |
| Operating Cash Flow | (117.75M) | (200.62M) |
| Capital Expenditures | (3.45M) | (3.51M) |
| Acquisitions (Net) | 0 | 0 |
| Purchases of Investments | (282.98M) | (164.73M) |
| Sales of Investments | 228.69M | 285.01M |
| Other Investing Activities | 10K | 0 |
| Investing Cash Flow | (57.73M) | 116.77M |
| Debt Repayment | (11.12M) | (8.16M) |
| Common Stock Issued | 0 | 0 |
| Common Stock Repurchased | 0 | 0 |
| Dividends Paid | 0 | 0 |
| Other Financing Activities | 6.13M | 14.25M |
| Financing Cash Flow | 91.33M | 28.06M |
| Effect of Forex Changes | 0 | 0 |
| Net Change in Cash | (84.15M) | (55.79M) |
| Free Cash Flow | (121.2M) | (204.13M) |
Generate Biomedicines, Inc.
NASDAQ:GENB
Intrinsic Alpha fair value
Locked
Current Price
$10.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.